Naperville, IL -- (ReleaseWire) -- 12/20/2012 -- MediQuest Therapeutics, Inc. - Product Pipeline Review - 2012 provides data on the MediQuest Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.
- MediQuest Therapeutics, Inc. - Brief MediQuest Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of MediQuest Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of MediQuest Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the MediQuest Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.
Reasons to buy
- Evaluate MediQuest Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of MediQuest Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the MediQuest Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with MediQuest Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of MediQuest Therapeutics, Inc. and identify potential opportunities in those areas.
To view table of contents for this market report please visit: